Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F12%3A8048" target="_blank" >RIV/00064203:_____/12:8048 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11130/12:8048 RIV/00843989:_____/12:00102483

Result on the web

<a href="http://dx.doi.org/10.1056/NEJMoa1113572" target="_blank" >http://dx.doi.org/10.1056/NEJMoa1113572</a>

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism

Original language description

In a randomized, open-label, event-driven, noninferiority trial involving 4832 patients who had acute symptomatic pulmonary embolism with or without deep-vein thrombosis, we compared rivaroxaban (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with standard therapy with enoxaparin followed by an adjusted-dose vitamin K antagonist for 3, 6, or 12 months. The primary efficacy outcome was symptomatic recurrent venous thromboembolism. The principal safety outcome was major or clinically relevant nonmajor bleeding.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FE - Other fields of internal medicine

OECD FORD branch

—

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2012

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

New England Journal of Medicine

ISSN

0028-4793

e-ISSN

—

Volume of the periodical

366

Issue of the periodical within the volume

14

Country of publishing house

US - UNITED STATES

Number of pages

11

Pages from-to

1287-1297

UT code for WoS article

000302343000006

EID of the result in the Scopus database

—